leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...199200201202203204205206207208209...235236»
  • ||||||||||  Alymsys (bevacizumab-maly) - Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi / Iko, Stada
    Trial completion, Enrollment change, Trial primary completion date:  Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN (clinicaltrials.gov) -  May 21, 2016   
    P1,  N=142, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=100 --> 142 | Trial primary completion date: Apr 2016 --> Oct 2015
  • ||||||||||  BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
    New P3 trial, Metastases:  INVICTAN (clinicaltrials.gov) -  May 18, 2016   
    P3,  N=120, Not yet recruiting, 
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial primary completion date, Combination therapy, Metastases:  Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) -  May 13, 2016   
    P2,  N=375, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Jun 2016
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi
    Enrollment closed, Trial primary completion date, Metastases:  FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer (clinicaltrials.gov) -  May 10, 2016   
    P2,  N=64, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Sep 2016
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  May 9, 2016   
    P2,  N=12, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Sep 2016 Trial primary completion date: Jul 2016 --> Jan 2017
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Enrollment closed, Trial primary completion date, Metastases:  A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) -  May 6, 2016   
    P1,  N=9, Active, not recruiting, 
    Trial primary completion date: Jul 2016 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
    Enrollment open, Enrollment change, Combination therapy, Metastases:  Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) -  May 6, 2016   
    P1,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016 Not yet recruiting --> Recruiting | N=80 --> 60
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion, Trial initiation date, Trial primary completion date, Metastases:  The Study of Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) -  May 4, 2016   
    P1/2,  N=73, Completed, 
    Active, not recruiting --> Completed Enrolling by invitation --> Completed | Initiation date: Aug 2011 --> Mar 2012 | Trial primary completion date: Feb 2012 --> Apr 2016
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial primary completion date, Metastases:  FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma (clinicaltrials.gov) -  Apr 22, 2016   
    P2,  N=35, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Sep 2017
  • ||||||||||  telisotuzumab (h224G11) / AbbVie
    Trial primary completion date, Metastases:  Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 22, 2016   
    P1,  N=124, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Sep 2017 Trial primary completion date: Apr 2016 --> Oct 2016